. Author manuscript; available in PMC: 2013 Dec 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2012 Dec 15;61(5):593–599. doi: 10.1097/QAI.0b013e3182717c98

Table 2.

PK parameter ratios of microdose regimen to standard dose regimen. Paired analysis, median (range)

Drug treatment	Sample	t_1/2	C_max	AUC_0-inf	Vd/F	CL/F
ZDV	Plasma	1.04 (0.48–1.43)	0.70^* (0.54–0.90)	0.90 (0.77–1.11)	1.04 (0.51–1.85)	1.11 (0.90–1.29)
	PBMC	1.02 (0.24–2.04)	4.47^* (1.79–25.17)	3.87^* (1.20–19.34)	N/A	N/A
	CD4+	0.62 (0.20–0.96)	16.97^* (3.43–20.11)	12.90^* (2.41–23.99)	N/A	N/A
TDF	Plasma	0.73 (0.47–1.27)	1.58^* (1.14–1.86)	1.53^* (1.05–2.07)	0.51^* (0.40–0.61)	0.66^* (0.48–0.96)
	PBMC	2.39 (0.44–8.12)	1.12 (0.53–1.64)	1.43 (0.76–4.81)	N/A	N/A
	CD4+	0.76 (0.24–2.77)	1.62 (0.89–3.46)	1.28 (0.96–2.74)	N/A	N/A

p<0.05, Wilcoxon signed rank test.